Navigation Links
Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
Date:7/16/2009

Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented in "Molecular Cancer" with respect to REOLYSIN, the Company's expectations related to the results of trials investigating delivery of REOLYSIN, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
2. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
3. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2, 2014  InfinityQS International, Inc., the global ... announces key client speakers for Infusion Chicago, its ... The event will be held Oct. 9-10, 2014, ... include projects from Coloplast, The Kellogg Company, Biomet, ... King. The two-day event will also include best ...
(Date:10/2/2014)...  AxelaCare Health Solutions, www.axelacare.com , a leading ... it has acquired Advanced Care, a New ... of the transaction were not disclosed. The ... to 18 nationwide and expands AxelaCare,s national home IV ... - New Jersey metro area.  AxelaCare ...
(Date:10/2/2014)...   Intarcia Therapeutics, Inc. today announced successful ... clinical trials for ITCA 650 (exenatide, delivered continuously once ... The first trial, FREEDOM-1, was a placebo-controlled, double-blind phase ... of ITCA 650 in patients with type 2 diabetes ... significantly superior to placebo for both 40 mcg and ...
Breaking Medicine Technology:InfinityQS Infusion Chicago to Spotlight Manufacturers' Key Successes in Achieving Enterprise Quality 2InfinityQS Infusion Chicago to Spotlight Manufacturers' Key Successes in Achieving Enterprise Quality 3AxelaCare Health Solutions Acquires Advanced Care of New York 2AxelaCare Health Solutions Acquires Advanced Care of New York 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5
... Health Inc, Morrisville, NC has introduced IronUp, a Liquid ... dietary iron for infants and children who do not ... (Photo: http://photos.prnewswire.com/prnh/20110810/CL49882 ) ... supplement from a bioavailable source of iron that is ...
... 9, 2011 Q2 2011 Highlights (compared to ... 9% to $109.6 million Product revenue rose 17% to $102.6 ... 2% to 37,300 Masimo rainbow revenue rose 26% to $9.1 ... prior period, which included $0.01 in one-time expenses.  Excluding the prior ...
Cached Medicine Technology:YASOO Health Introduces IronUp™ 2Masimo Reports Second Quarter 2011 Financial Results 2Masimo Reports Second Quarter 2011 Financial Results 3Masimo Reports Second Quarter 2011 Financial Results 4Masimo Reports Second Quarter 2011 Financial Results 5Masimo Reports Second Quarter 2011 Financial Results 6Masimo Reports Second Quarter 2011 Financial Results 7Masimo Reports Second Quarter 2011 Financial Results 8
(Date:10/2/2014)... (PRWEB) October 02, 2014 USARAD ... teleradiology and telemedicine solutions provider including its SecondOpinions.com® ... Backhaus have joined its Executive Team as President ... , Brent Backhaus, USARAD’s new President and COO, ... years of progressively responsible experience in commercial-, medical- ...
(Date:10/2/2014)... Social-Engineer, Inc. the leader in security testing and ... a complimentary webinar on Friday, October 31, at 1:00PM ... of the annual Social-Engineer Capture the Flag (SECTF) competition ... explore how to maximize security and employee performance to ... the webinar go to: Free Webinar Registration . ...
(Date:10/2/2014)... is a distinguished bamboo product manufacturer and retailer. Plenty ... global customers in the past few years. Now, the ... All its online workers are professional and patient; they ... company has recently added a new assortment of ... marketing specialist has announced that all these brand new ...
(Date:10/2/2014)... may interact with stress to trigger heart disease in some ... in about 13 percent of people, but only in those ... their heart disease risk through simple measures such as ... researchers said. The study authors analyzed genetic data from ... in the EBF1 gene and higher levels of central obesity, ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay News) -- ... may face an increased risk of dying in the next several ... older Americans, researchers found those who were unable to detect scents ... as likely to die in the next five years, versus those ... the inability to distinguish odors -- was a bigger predictor of ...
Breaking Medicine News(10 mins):Health News:Teleradiology and Telemedicine Pioneers Brent Backhaus and Lorna Backhaus Join USARAD Holdings, INC. & SecondOpinions.com® 2Health News:Teleradiology and Telemedicine Pioneers Brent Backhaus and Lorna Backhaus Join USARAD Holdings, INC. & SecondOpinions.com® 3Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 2Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 3Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3
... - Promotes Commercial Products at Major Cardiology Conferences - - ... - Achieves Efficiencies and Conserves Cash by Consolidating R&D ... ... Neovasc Inc. (TSXV: NVC), a,new specialty vascular device company, today reported on ...
... A very difficult-to-treat child leukemia may benefit from the ... launches the cancer but could potentially be reversed ... The study, led by researchers at Children,s Hospital Boston ... in the November 4 issue of Cancer Cell ...
... Rhode Island Hospital researchers have identified genetic proteins, also ... the microscopic level that can signal a precancerous condition ... who are likely to progress to esophageal cancer. This ... journal Clinical Cancer Research . , Barrett,s esophagus ...
... DUBLIN, Calif., Nov 3 SuperGen, Inc. (Nasdaq:,SUPG), ... development,of novel cancer therapies, today announced that James ... scheduled to present at the,Rodman & Renshaw 10th ... the New York Palace Hotel., SuperGen,s presentation ...
... Global Awards Ceremony Featuring Performances by Grammy Award ... Country Music Star Kenny Rogers, OAK BROOK, ... hosted its 24th Annual Awards of Excellence,celebration on ... who have made outstanding contributions to improve the ...
... CONCORD, Mass., Nov. 3 The Melanoma,Foundation of ... to its fall symposium: "Updates in Melanoma Treatment",presented ... Melanoma Program at Dana,Farber Cancer Institute. A portion ... "Immunotherapy: A Panel Presentation," which includes a panel ...
Cached Medicine News:Health News:Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options 2Health News:Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options 3Health News:Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options 4Health News:Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options 5Health News:Tackling a hard-to-treat childhood cancer by targeting epigenetic changes 2Health News:New research finds markers for esophageal cancer before it develops 2Health News:Ronald McDonald House Charities(R) Awards of Excellence Honors Peter and Virginia Ueberroth, Dr. Catherine D. Deangelis and Lionel Whitehead 2Health News:Ronald McDonald House Charities(R) Awards of Excellence Honors Peter and Virginia Ueberroth, Dr. Catherine D. Deangelis and Lionel Whitehead 3
IVUS console...
FemoStop system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic and i...
VasoSeal ES is a extravascular arterial sealing. It utilizes a unique temporary arterial locator system which provides an easier and surer method of locating the femoral artery....
... was the first device ... after diagnostic and interventional ... It is a collagen-based ... for immediate sheath removal ...
Medicine Products: